Medicenna Therapeutics (TSE:MDNA) Posts Earnings Results

Posted by on Jun 26th, 2026

Medicenna Therapeutics (TSE:MDNA – Get Free Report) posted its quarterly earnings data on Thursday. The company reported C($0.05) earnings per share for the quarter, FiscalAI reports. Medicenna Therapeutics had a negative net margin of 533,640.00% and a negative return on equity of 103.51%.

Medicenna Therapeutics Stock Up 1.2%

MDNA opened at C$0.41 on Friday. The business’s fifty day simple moving average is C$0.51 and its 200 day simple moving average is C$0.74. Medicenna Therapeutics has a 52 week low of C$0.38 and a 52 week high of C$1.97. The company has a quick ratio of 4.65, a current ratio of 2.68 and a debt-to-equity ratio of 3.30. The stock has a market cap of C$34.62 million, a PE ratio of -2.77 and a beta of 2.89.

Medicenna Therapeutics Company Profile

(Get Free Report)

Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment. The have the potential to purge the tumor and un-blind the immune system to cancer thereby altering the treatment paradigm for a large majority of cancer patients.

Featured Articles

Receive News & Ratings for Medicenna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicenna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.